by Raynovich Rod | Nov 19, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 11/20;25…..Abbott enters cancer care business with $21B acquisition of Exact Sciences (EXAS) with Cologuard Screening tests. Will add $3B in revenue in 2025 and be part of a subsidiary with $12B in sales annually. This is a $60B market for cancer...
by Raynovich Rod | Nov 13, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 11/15 Merck buys Cedara for $9.2B for long acting Flu drug. An alternative to vaccines? CDTX up 105% IBB at $164.30 approaching highs of AUG 2021 of $177. Large Cap Biopharma Stocks Lead the Way for Healthcare Investors Biopharma stocks offer growth plus...
by Raynovich Rod | Nov 10, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
An abrupt reversal from “Risk-Off” sentiment launched a rally in some SMID biotechs, precious metals and AI / Semiconductor stocks. The NAZ was up 2.25%. Health Science stocks did well today: Precision oncology, biopharmaceuticals weight-loss /obesity A...
by Raynovich Rod | Oct 27, 2025 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-6 11/10/25…SMID Biotechs in a romp!…Cogent Biosciences (COGT) up 130% on Phase 3 Study. XBI up 1.5% at $110 level. Update-5…11:11a 11/7/25…XBI slices thru support of 20 day down 2.4% to $106 level-a red screen day. Moreover all SMID...
by Raynovich Rod | Oct 26, 2025 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 …10/27…SMID BIOTECH rally on a green screen day.. many hot biotechs in Russell 2000: AXSM, BBIO,CYTK, CRNX, TEM etc Today we read on Bloomberg at 10a about a deal that said Novartis (NVS) will buy Avidity Biosciences (RNA) for $72 share....
by Raynovich Rod | Oct 23, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
HEALTHCARE Stocks Are Coming Back Led by Biopharma so what’s next? The XLV portfolio weighting has shifted to LargeCap Biopharma which has performed well (see our articles). Biotech has shown strong momentum in Q3 with SMID caps leading: IBB up 16.3% YTD and...
by Raynovich Rod | Oct 15, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-4 10/22/25,,,Small cap biotech momentum rally fizzles on profit taking. Healthcare investors should look at Medtech and US Medical Devices with the IHI and health sciences sector with FSMEX. Update at end of the day. TMO up 19% MTD at $563. Healthcare sector...
by Raynovich Rod | Oct 7, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-3 10/14…A volatile mixed day with a slight shift away from large cap tech to speculative small caps favoring biotechs. Regional banks strong. Rare earth conflicts with China .Looking at our SMID cap trading list today: XNCR down 11% on profit taking after...
by Raynovich Rod | Sep 29, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 10/2/25… MAJOR Market Indexes compared to biotech: QQQ up 18.48% at $605.73, S&P 500 (SPY) up 14.19% at $669.22, DJI up 9.34% at 46,519. Ark Genomic Revolution (ARKG) up 26.58% ytd at $29.81. iShares biotechnology ETF (IBB) up 13.17% ytd at...
by Raynovich Rod | Sep 22, 2025 | Biopharmaceuticals
Update-1 9/24/25…A quiet day in biotech except for uniQure N.V.(QURE) soaring over 247% tp $47.50 on a potential gene therapy (AMT-130) cure for Huntington’s Disease!. Huntington’s disease is an inherited condition in which nerve cells in the brain break...
